Immune Response News and Research

RSS

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

Researchers at Penn State College of Medicine now better understand the role of a protein, interleukin-21 (IL-21), in the immune system response to infections in the nervous system.

6 Oct 2020

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

A recent paper published in the preprint server medRxiv in September 2020 discusses the “clinically relevant variation in the expression of COVID-19-related genes”, which is associated with the host and environmental factors, as well as host genetic factors.

6 Oct 2020

New findings could improve investigation of T cell response to COVID-19

Researchers in the United States have made an important discovery about the processing and presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral peptides that provides a better understanding of the immune response to coronavirus disease 2019 (COVID-19) and may help facilitate the design of improved vaccines.

5 Oct 2020

Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response

A group of researchers from Australia and China recently demonstrated how SARS-CoV-2 spike glycoprotein subunit 1 can induce a pro-inflammatory signaling pathway (leading to cytokines deployment and epithelial damage in human bronchial epithelial cells), but also highlighted the potential of peptide-based antivirals in tackling this novel coronavirus.

5 Oct 2020

Less than 10% of US adults have SARS-CoV-2 antibodies

A new study by researchers at Stanford University and Ascend Clinical Laboratory and published in the journal The Lancet in September 2020 reports the prevalence of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in a dialysis patient population in the US.

5 Oct 2020

Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 Oct 2020

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

5 Oct 2020

Ludwig study uncovers a nutritional approach to improve cancer immunotherapy

A Ludwig Cancer Research study has uncovered a mechanism by which the tumor's harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response.

5 Oct 2020

Will COVID-19 become a seasonal virus?

In this interview, Dr. Hadi Yassine and Dr. Hassan Zaraket speak about their research into whether COVID-19 will become a seasonal virus.

5 Oct 2020

Sebum changes in COVID-19 patients, for future testing and prognosis

Now, a new study published on the preprint server medRxiv in September 2020 shows that sebum lipids change in COVID-19. This could help develop a cheap and straightforward method of non-invasive diagnosis.

5 Oct 2020

Another study finds cross-reactivity T cell responses against SARS-CoV-2

Using ELISpot and proliferation assays, researchers show strong responses in SARS-CoV-2 infected patients, but not so much in negative samples. However, there may be cross-reactive T cell responses from other human coronaviruses.

5 Oct 2020

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for assessing SARS-CoV-2 antibody assays and show robust performance metrics for the AbC-19 rapid test.

5 Oct 2020

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.

4 Oct 2020

Study reveals how immune cells sacrifice themselves to help fight off infections

Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

1 Oct 2020

Study reveals how ILCs develop, adapt, specialize in specific tissue environments

Specialized immune cells settle permanently in various tissues of the body and build "local task forces". Scientists from Würzburg have now discovered, how these cell populations can renew locally and can adapt to their specific environment.

1 Oct 2020

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

30 Sep 2020

Study shows how human cells fight viral infections with the emergence of SARS-CoV-2

Science's pursuits of unraveling how human cells fight viral infections kicked into high gear in 2020 with the devastating emergence of the SARS-CoV-2 virus.

30 Sep 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

Novel nasal treatment could protect people from COVID-19

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal.

30 Sep 2020

Immune Response News and Research

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

New findings could improve investigation of T cell response to COVID-19

Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response

Less than 10% of US adults have SARS-CoV-2 antibodies

Macrophage subgroups may play pivotal role in COVID-19 lethality

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Ludwig study uncovers a nutritional approach to improve cancer immunotherapy

Will COVID-19 become a seasonal virus?

Sebum changes in COVID-19 patients, for future testing and prognosis

Another study finds cross-reactivity T cell responses against SARS-CoV-2

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Study reveals how immune cells sacrifice themselves to help fight off infections

Study reveals how ILCs develop, adapt, specialize in specific tissue environments

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

Study shows how human cells fight viral infections with the emergence of SARS-CoV-2

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

Researchers identify a new method to produce miniaturized antibodies

Novel nasal treatment could protect people from COVID-19

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News